Search

Displaying results 1581 - 1590 of 4233 in total
  1. Drug

    Rabies immune globulin, human

    go.drugbank.com/drugs/DB11603
    Approved

    If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies

  2. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

  3. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.

  4. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

  5. Drug

    Succimer

    go.drugbank.com/drugs/DB00566
    ApprovedInvestigational

    A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.

  6. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

  7. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102] … [L51078] In July 2024, the US FDA rejected the approval of insulin icodec, citing concerns regarding hypoglycemia and the indication being sought for type 1 diabetes mellitus.

  8. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot ...

  9. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.

  10. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.